Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adjusted annual percentage of quality indicators by prescription

Published byΣπυρίδιον Σπυρόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Adjusted annual percentage of quality indicators by prescription"— Presentation transcript:

1 Adjusted annual percentage of quality indicators by prescription
Adjusted annual percentage of quality indicators by prescription. *Excluding patients with kidney and vesicoureteral disorders or renal failure. †Separate multivariate logistic regression models were constructed for each quality indicator. Adjusted annual percentage of quality indicators by prescription. *Excluding patients with kidney and vesicoureteral disorders or renal failure. †Separate multivariate logistic regression models were constructed for each quality indicator. Percentages were calculated from the logistic regression model parameter estimates and are shown here. HbA1c, glycated hemoglobin. Hirokazu Tanaka et al. BMJ Open Diab Res Care 2016;4:e000291 ©2016 by American Diabetes Association

Download ppt "Adjusted annual percentage of quality indicators by prescription"

Similar presentations

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Diabetes hazard rates by number of visits with reported statin use.

Diabetes hazard rates by number of visits with reported statin use.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Differences in the glycated hemoglobin (HbA1c) levels.

Differences in the glycated hemoglobin (HbA1c) levels.
Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
Map of the USA (including Alaska, Hawaii and Puerto Rico), showing the mean annual temperature and the magnitude of the β coefficientsa from the obesity-adjusted.

Map of the USA (including Alaska, Hawaii and Puerto Rico), showing the mean annual temperature and the magnitude of the β coefficientsa from the obesity-adjusted.
Illustration of the causal inference scheme.

Illustration of the causal inference scheme.
Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.

Glycated hemoglobin (HbA1c) trajectories among children during the first 5 years after diagnosis of type 1 diabetes, stratified by diagnostic era and diagnostic.
The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.
Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),
The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,

Screening, enrollment, and randomization of study participants (BMI, body mass index; CTG, conventional therapy group; HbA1c, glycated hemoglobin; HDL-C,
(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.

(A) Kaplan-Meier renal survival estimates of patients with diabetic nephropathy (DN), non-diabetic renal disease (NDRD) and mixed groups, adjusting for.
Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.

Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Similar presentations

Ads by Google